Department of Chemistry, University of Colorado at Colorado Springs, Colorado Springs, CO 80918, USA.
Future Med Chem. 2010 Jan;2(1):81-92. doi: 10.4155/fmc.09.147.
Inosine monophosphate dehydrogenase (IMPDH) catalyzes the rate-limiting step in the de novo biosynthesis of guanine nucleotides. In recent years it has become the target of multiple drugs in an attempt to cure a variety of diseases. Possible therapeutic drugs range from antiviral and anticancer to immunosuppressive targets. Research has shown that if IMPDH is effectively inhibited, cancerous growth can be slowed and virus replication can be stopped. Microbial and parasitic IMPDH differ significantly from the human isoforms and targeting those isoforms could lead to effective treatments for many diseases. Inhibiting IMPDH is an extremely promising therapy for a variety of disease states. Isoform- and species-selective inhibition is desirable and scientists are making significant progress in these areas.
肌苷单磷酸脱氢酶（IMPDH）催化从头合成鸟嘌呤核苷酸的限速步骤。近年来，它已成为多种药物的靶点，试图治疗各种疾病。可能的治疗药物范围从抗病毒和抗癌到免疫抑制靶点。研究表明，如果有效地抑制 IMPDH，癌细胞的生长可以减缓，病毒复制可以停止。微生物和寄生虫的 IMPDH 与人同工酶有很大的不同，针对这些同工酶可能会为许多疾病带来有效的治疗方法。抑制 IMPDH 是治疗多种疾病状态的一种极有前途的方法。同工酶和物种选择性抑制是理想的，科学家们在这些领域取得了重大进展。
